Background. Human immunodeficiency virus (HIV)-infected persons have a high incidence of pneumonia and pneumococcal disease. Benefits of vaccination with the 23-valent pneumococcal polysaccharide vaccine (PPV) among these patients continue to be debated.
monia due to all causes and the rate of invasive pneumococcal disease is several-fold higher among HIV-infected persons than among the general population [2] . The incidence of invasive pneumococcal disease among HIV-infected patients has decreased since the introduction of HAART [3] [4] [5] , but it continues to be substantially higher than that observed among HIVuninfected matched control subjects [2, [6] [7] [8] . Black HIV-infected patients represent a group with one of the highest incidences of disease [8] .
Vaccination with 23-valent pneumococcal polysac-charide vaccine (PPV) is the main strategy pursued in the United States to prevent morbidity and mortality related to pneumococcal infections [9, 10] , and PPV vaccination is indicated for adults with risk factors for pneumococcal disease.
In the population at highest risk, PPV vaccination offers protection against bacteremia, but protection against pneumonia has not been clearly established [11, 12] . Among HIV-infected persons, the current recommendations for vaccination with PPV are largely based on expert opinion [13] . The only prospective study evaluating the efficacy of vaccination among HIV-infected persons was performed in Uganda and revealed a significantly increased rate of pneumococcal disease during the first 6 months after vaccination [14] . In contrast, retrospective studies from North America have shown that PPV protects against pneumococcal disease among certain groups of HIV-infected patients, specifically among those vaccinated while their CD4 cell count was у500 cells/mm 3 [15] or 1200 cells/mm 3 [16] or while they were receiving HAART [4, 15] . These studies have not controlled for the presence of other medical comorbidities in their cohorts.
The Veterans Aging Cohort 5-Site Study (VACS 5) is an ongoing prospective study consisting of HIV-infected and HIVuninfected patients. The VACS 5 HIV-infected group is composed of older participants, compared with other HIV-infected cohorts [17] ; the group consists of a high proportion of black individuals, has a high rate of smoking, and has a high prevalence of comorbidities. As such, this cohort is well suited to evaluate the protective effect of PPV vaccination among HIVinfected persons, while controlling for other factors that can increase this group's risk of pneumonia and pneumococcal disease. With this objective, we evaluated the incidence of pneumonia and pneumococcal disease following vaccination with PPV among HIV-infected and HIV-uninfected participants in VACS 5.
METHODS
VACS 5 is an ongoing prospective study consisting of HIVinfected patients who were block-matched to HIV-uninfected patients on the basis of 5-year increments of age, ethnicity, and location and who were enrolled during 2001-2002 from the outpatient infectious diseases and general medicine clinics at 5 Veterans Affairs (VA) medical centers. At study entry, participants completed a comprehensive self-administered survey (available at http://www.vacohort.org). The institutional review boards at all locations approved the study, and all participants provided written informed consent. This study is fully described elsewhere [17] .
VACS 5 participants were stratified by PPV vaccination status. Dates for vaccination were established by retrospective review of the VA electronic administrative and medical records. If a patient had received PPV at any time during the 3 years before and 2 years after the survey date, they were considered to be vaccinated. Patients who had not been vaccinated during that time were considered to be unvaccinated. All HIV-infected patients received PPV after the diagnosis of HIV infection was made. The PPV vaccination date and the survey date were established as the index date (date at which follow-up for the primary outcome started) for the vaccinated and unvaccinated patients, respectively. Exclusion criteria were (1) !1 year of observation after the index date, (2) hospitalization for pneumonia during the year before the index date (because these patients are at increased risk of subsequent pneumonia and the diagnosis of pneumonia may have prompted the vaccination) [18, 19] , (3) and female sex ( ; because of the small n p 52 numbers). The maximal extent of follow-up for clinical events was established at 2 years after the index date.
Our primary outcome was the incidence of pneumonia. International Classification of Diseases, Ninth Revision (ICD-9) codes for pneumonia and dates of occurrence were obtained from patient treatment files in the VA electronic medical records. A pneumonia event was defined as an outpatient or inpatient ICD-9 code for pneumonia due to a nonspecified organism or for a pneumococcal-specific diagnosis. If no other diagnoses were specified, cases of pneumococcal bacteremia and sepsis were considered as pneumonia events. Specific nonpneumococcal pneumonia diagnoses (e.g., Pneumocystis carinii pneumonia, pulmonary tuberculosis, and Haemophilus influenza pneumonia) were excluded.
Additional variables were as follows: age, ethnicity, Alcohol Use Disorder Identification Test result, drug use, and current smoking status (all data were obtained from the patient's survey); the underlying conditions of interest, alcohol and drug dependence, chronic obstructive pulmonary disease and/or asthma, coronary artery disease and/or congestive heart failure, diabetes mellitus, lung cancer, and other malignancies (all were determined by ICD-9 codes, as described elsewhere [20, 21] ); hemoglobin level, CD4 cell count, and HIV load (value closest to the survey date within 6 months; obtained from the laboratory package); and antiretroviral use (HAART vs. non-HAART; obtained from the pharmacy package). The reference date for the above variables was the date of survey completion, which, for unvaccinated patients, was the index date; for vaccinated patients, the survey and index dates (vaccine date) were different.
Statistical analysis. The primary outcome was defined as the occurrence of a first pneumonia event during the observation time. The time to event was calculated as the difference in days between the event date and the index date. Because the present analytic study focused on the association between vaccination and risk of an event, neither of which was part of the sampling scheme, the sampling weights were not used in the analysis, and those variables used in the sample design were included as covariates to control for potential residual confounding. Comparisons of continuous variables were performed using Student's t tests and analysis of variance, and comparisons between categorical variables were performed using x 2 tests. The risk for the event was compared by PPV vaccination status and HIV infection status. Cox proportional hazards regression models were used to determine the hazard ratio (HR), controlling for age; ethnicity; tobacco use; alcohol use; drug use; diagnosis of chronic obstructive pulmonary disease and/or asthma, coronary artery disease and/or congestive heart failure, diabetes, or cancer; and hemoglobin level; for HIV-infected patients, these models were used, controlling for CD4 cell count and viral load. Results are expressed as HRs with 95% CIs. The proportionality assumption was met for all analyses. All analyses were conducted using SAS, version 9.1 (SAS Institute).
RESULTS
The VACS 5 sample included 1719 male patients. Fifty patients (10% of whom were vaccinated and 80% of whom were infected with HIV) were excluded because they died within 1 year after study entry; more HIV-infected patients than HIVuninfected patients died within 1 year after study entry (4% vs. 1%;
). An additional 43 patients were excluded be-P ! .01 cause they had experienced pneumonia events in the year before the index date; more HIV-infected patients than HIV-uninfected patients experienced such events (4% vs. 1%;
). P ! .01 There were 1626 patients remaining in the analytic sample (692 HIV-uninfected patients and 934 HIV-infected patients). Seventy-five percent of the vaccinated patients received PPV before the survey date, and 50% of all vaccinated patients received PPV within 1 year of the survey date.
Characteristics of HIV-infected patients, compared with HIV-uninfected patients. Compared with HIV-uninfected patients, HIV-infected patients were younger (49.2 vs. 55.4 years;
), more likely to be African American (55% vs. P ! .01 44%;
), more likely to smoke (44% vs. 34%; ), P ! .01 P ! .01 and more likely to have received an ICD-9 diagnosis of alcohol dependence (24% vs. 17%; ) or drug dependence (30% P ! .01 vs. 15%;
). HIV-uninfected patients were more likely P ! .01 than HIV-infected patients to have received diagnoses of coronary artery disease and/or congestive heart failure (17% vs. 6%;
), diabetes (24% vs. 14%; ), and cancer (19% P ! .01 P ! .01 vs. 14%;
) and had a higher mean number of medical P ! .05 comorbidities (1.8 vs. 1.4;
). HIV-infected patients had P ! .01 lower hemoglobin levels than did HIV-uninfected patients (14 g/dL vs. 14.2 g/dL;
). P ! .05 Characteristics of vaccinated patients, compared with unvaccinated patients. Overall, 59% of patients had been vaccinated; HIV-infected patients were more likely than HIV-uninfected patients to have been vaccinated (69% vs. 46%; P ! ). Vaccinated and unvaccinated patients did not dif-P ! .01 fer with regard to ethnicity, smoking status, alcohol use at the time of the survey, or hemoglobin level. The incidence of pneumonia events during the observation period was similar among all vaccinated and all unvaccinated patients (6% vs. 6%; P p ). .964
Characteristics of patients stratified by HIV infection status and vaccination status. Vaccinated HIV-uninfected patients were significantly older than unvaccinated HIV-uninfected patients and both vaccinated and unvaccinated HIV-infected patients (table 1) . Unvaccinated HIV-infected patients were more likely to be black or Hispanic than either vaccinated HIV-infected patients or vaccinated HIV-uninfected patients.
Vaccinated HIV-infected patients were significantly more likely than patients in the other groups to be current smokers. Compared with the other groups, unvaccinated HIV-infected patients were significantly more likely to have received a diagnosis of alcohol abuse or dependence or drug use disorders and to have lower hemoglobin levels. Vaccinated HIV-uninfected patients had a significantly higher mean number of comorbid conditions (2.37 comorbid conditions), compared with the other groups. There was no significant difference in CD4 cell count between vaccinated and unvaccinated HIV-infected patients; however, unvaccinated patients had a significantly higher mean log viral load ( ). P ! .01 Effects of vaccination status, HIV infection status, and clinical characteristics on pneumonia events. Ninety-seven pneumonia events (in 6% of the patients) occurred during the study period. Fourteen of the events (14%) were related to pneumococcal-specific diagnoses (1 septicemia and pneumonia, 3 pneumonia, and 10 bacteremia). The remaining events were associated with pneumonia due to nonspecified organisms. HIV-infected patients were more likely than HIV-uninfected patients to have experienced a pneumonia event during the observation period (9.1% vs. 1.7%;
) and during the P ! .01 0-6-month (2.9% vs. 0.4%), 6-12-month (2.6% vs. 0.7%), and 12-24-month (3.6% vs. 0.6%) periods. There was no significant difference in the age of patients with and without pneumonia. However, patients with pneumonia were more likely to be current smokers (49.5% vs. In an analysis of time to a pneumonia event (figure 1), HIVinfected patients had a higher risk of pneumonia, compared with HIV-uninfected patients (HR, 5.81; 95% CI, 3.15-10.71), and overall, vaccinated patients had a nonsignificant trend toward less risk for pneumonia (HR, 0.75; 95% CI, 0.50-1.13) (table 2). The interaction of HIV infection status and vaccination status was not significant, indicating that, prior to controlling for HIV-specific and other variables, the effect of vaccination did not vary by HIV infection status ( ). In the P p .13 full model (table 2) , having HIV infection, having received a diagnosis of chronic obstructive pulmonary disease and/or asthma, and having a low hemoglobin level were significant risk factors for pneumonia, and vaccination yielded a trend toward protection ( ). Additional nested models, per-P p .08 formed to reassess the effects after deleting nonsignificant terms one at a time, yielded no substantial changes.
Among HIV-infected patients, after controlling for HIV-specific variables, vaccination significantly reduced the risk of pneumonia (HR, 0.65; 95% CI, 0.42-1.00; ) (table 2 and P ! .05 figure 1 ). Among this group, smoking, low hemoglobin level, and low CD4 cell count at the time of the survey were risk factors for pneumonia, and low viral load yielded a trend toward protection ( ). P p .06 Among HIV-uninfected patients, vaccination was not significantly associated with a reduction in risk of pneumonia (HR, 0.85; 95% CI, 0.25-2.95), possibly because of lack of power to detect an effect. The HR for the medical comorbidities known to be associated with pneumonia was not statistically significant. However, a lower hemoglobin level at the time of the survey was associated with a trend for an increased risk ( ) . P p .07
DISCUSSION
In this study, we examined the effect of vaccination on the incidence of pneumonia events in a cohort of HIV-infected and HIV-uninfected patients with a high frequency of medical and substance use comorbidities. We found that HIV-infected patients had a significantly higher frequency of pneumonia events, compared with their HIV-uninfected counterparts, and that HIV-infected patients experienced a protective effect from PPV vaccination after controlling for HIV-related variables (CD4 cell count and viral load) and other medical comorbidities. Among the HIV-uninfected patients, we found no statistically significant benefit from vaccination, possibly because of lack of power to detect an effect.
The VACS 5 HIV-infected group is composed of older participants, compared with other HIV-infected cohorts [17] , and the group has a high proportion of black patients, a high rate of smoking, and a high prevalence of comorbidities, all of which are factors associated with increased risk of pneumococcal disease [2, 8, 22, 23] . Furthermore, black persons may obtain less protection from pneumococcal vaccination [22] . Yet, despite the numerous risk factors for pneumonia in our population, PPV vaccination was protective among the HIV-infected patients.
We did not find an increased risk of pneumonia events in the first 6 months following vaccination; the rate of pneumonia events was similar during the first and second 6-month periods and during the second year of observation. More than 70% of our HIV-infected patients were receiving HAART at the time of the survey. Use of HAART may explain the discrepant results between the Ugandan study [14] and studies from Europe and North America [4, 15, 16] . Both CD4 cell count and HIV viremia affect B cell responses among HIV-infected individuals, and HAART-induced improvements in either parameter translate into improvements of B cell function [24, 25] . In addition, HAART may induce improved qualitative and quantitative antibody responses to pneumococcal antigens [26, 27] . In our multivariate analysis, CD4 cell count but not viral load or use of HAART had a significant effect on the incidence of pneumonia among our patients.
Most observational studies show that PPV is effective in preventing invasive pneumococcal disease among older adults and adults with underlying medical conditions; however, its effectiveness in preventing pneumococcal pneumonia or pneumonia of any cause has been more difficult to demonstrate [28] . In our study, the lack of effectiveness of PPV among the HIV-uninfected group may have explanations other than the potential lack of vaccine efficacy. Among veterans receiving treatment, PPV is given routinely to those who have an indication for vaccination [9] . Consequently, the unvaccinated HIV-uninfected patients were younger and had a lower mean number of comorbid conditions, compared with the vaccinated HIV-uninfected patients. If the unvaccinated patients had been a matched group with similar risk for pneumonia, the effect of vaccination might have been evident.
We elected as an outcome the composite of specific pneumococcal diagnoses and diagnoses of pneumonia due to nonspecified organisms. We chose a broad definition, because in clinical practice, an etiologic diagnosis of pneumonia is rarely made [29] . Indeed, 86% of the pneumonia events that we examined were cases of pneumonia without a microbiologic diagnosis, and only 14% were specific pneumococcal disease diagnoses.
Our study has a number of strengths when examining the effect of vaccination on the incidence of pneumonia. The rates of vaccination and documentation of vaccination status within the VA system are high (driven by electronic clinical reminders and electronic documentation of all vaccinations, even if received outside the VA setting) [30] ; thus, the risk of biasing the results on the effectiveness of vaccination because of incorrect assignment of vaccination status was low. However, this bias is differential, and it could bias the estimate of effect in either direction. HIV-infected and HIV-uninfected participants in VACS 5 report 72% and 71% of their inpatient care and 82% and 83% of their outpatient care, respectively, from the VA [29] . In addition, all visits to outpatient clinics or emergency departments, as well as hospital admissions, that occur at any VA facility are documented through electronic medical records. Furthermore, within VACS 5, data collected from surveys complement the electronic chart information [17] . We included as an outcome both inpatient and outpatient diagnoses to maximize the chances of observing an effect and to eliminate the potential bias caused by clinicians being more inclined to admit to the hospital HIV-infected patients who present with pneumonia. Thus, the risk of biasing results because of inadequate detection of an event was also low and unlikely to be asymmetric by HIV infection or PPV vaccination status. There may still be other potential biases that we cannot account for, such as differential care-seeking behavior by HIV infection status among patients with symptoms suggestive of pneumonia.
One weakness of our analysis is that the survey information, laboratory data, and comorbidity data were linked to the survey date. For 50% of the vaccinated patients, the vaccine date and the survey date were 11 year apart; thus, conclusions from the analysis that take into consideration these parameters need to be interpreted with caution. In addition, patients classified as unvaccinated (no vaccination during the 3 years before the survey date) could have received PPV before that date. This misclassification would have biased our results toward the null. Because not all of the VACS 5 participants receive their inpatient and outpatient care at the VA, it is possible that we did not capture all of the clinical events of interest; however, because the percentage of VA use was similar between both HIV-infected and HIV-uninfected groups, the results should not have been differentially affected.
Consistent with prior studies, risk factors for pneumonia among HIV-infected patients were smoking and lower CD4 cell count [2, 16, 22, 31] . We also found that lower hemoglobin level was a risk factor for a pneumonia event. After adjusting for comorbidities and other variables, lower hemoglobin level remained significantly associated with the risk of pneumonia events among the whole group and among HIV-infected patients. This potential association has been described for pneumococcal [32] and other bacterial infections [33] and deserves further exploration.
In summary, we found that, among HIV-infected patients, PPV vaccination offered protection against pneumonia events. Because vaccination with PPV has minimal apparent clinical deleterious effect and, despite all of the caveats described above, may have a beneficial effect among this group at high risk for pneumonia, our findings support the current recommendation of vaccination of HIV-infected patients. In addition to immune preservation and reconstitution through HAART and pneumococcal vaccination, smoking cessation needs to be more aggressively implemented as a strategy for preventing pneumonia among HIV-infected patients.
